208 related articles for article (PubMed ID: 37852817)
21. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
[TBL] [Abstract][Full Text] [Related]
22. Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey.
Kopenhafer L; Thompson A; Chang J; Sikirica S; Masters ET; Cappelleri JC; Peck EY; Maculaitis MC
Urol Oncol; 2024 Mar; 42(3):70.e1-70.e10. PubMed ID: 38272755
[TBL] [Abstract][Full Text] [Related]
23. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
[TBL] [Abstract][Full Text] [Related]
24. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
25. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
26. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
27. Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG.
Anderson CB; Chen L; Chang SS; McKiernan JM; Wright J
Clin Genitourin Cancer; 2022 Dec; 20(6):595-603. PubMed ID: 35948482
[TBL] [Abstract][Full Text] [Related]
28. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
30. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A
World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732
[TBL] [Abstract][Full Text] [Related]
32. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
Wang E; Hagberg O; Malmström PU
PLoS One; 2023; 18(12):e0292174. PubMed ID: 38096211
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
[TBL] [Abstract][Full Text] [Related]
34. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
Lone Z; Benidir T; Wood A; Campbell RA; Alaghehbandan R; Li J; Haber GP; Eltemamy M; Haywood SC; Weight CJ; Lee BH; Almassi N
Urol Oncol; 2024 Mar; 42(3):71.e1-71.e7. PubMed ID: 38135626
[TBL] [Abstract][Full Text] [Related]
35. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.
Williams SB; Howard LE; Foster ML; Klaassen Z; Sieluk J; De Hoedt AM; Freedland SJ
JAMA Netw Open; 2021 Mar; 4(3):e213800. PubMed ID: 33787908
[TBL] [Abstract][Full Text] [Related]
36. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
37. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
38. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
39. The bladder microbiota is not significantly altered by intravesical BCG therapy.
Heidrich V; Mariotti ACH; Inoue LT; Coser EM; Dos Santos EX; Dos Santos HDB; Asprino PF; Bettoni F; Costa GAP; Bastos DA; Jardim DL; Arap MA; Camargo AA
Urol Oncol; 2024 Jan; 42(1):22.e13-22.e21. PubMed ID: 38030469
[TBL] [Abstract][Full Text] [Related]
40. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]